ITOS - iTeos Therapeutics, Inc. Stock Price, Fair Value and News

10.78USD+0.22 (+2.08%)Market Closed

Market Summary

USD10.78+0.22

Market Closed

2.08%

ITOS Stock Price

View Fullscreen

ITOS RSI Chart

ITOS Valuation

Market Cap

386.4M

Price/Earnings (Trailing)

-3.43

Price/Sales (Trailing)

30.68

EV/EBITDA

-1.25

Price/Free Cashflow

-3.62

ITOS Price/Sales (Trailing)

ITOS Profitability

EBT Margin

-865.66%

Return on Equity

-19.58%

Return on Assets

-16.87%

Free Cashflow Yield

-27.62%

ITOS Fundamentals

ITOS Revenue

Revenue (TTM)

12.6M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ITOS Earnings

Earnings (TTM)

-112.6M

Earnings Growth (Yr)

-249.37%

Earnings Growth (Qtr)

5.24%

Breaking Down ITOS Revenue

Last 7 days

-9.9%

Last 30 days

-4.6%

Last 90 days

0.1%

Trailing 12 Months

-22.8%

How does ITOS drawdown profile look like?

ITOS Financial Health

Current Ratio

13.76

ITOS Investor Care

Shares Dilution (1Y)

0.59%

Diluted EPS (TTM)

-3.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	127.7M	86.0M	66.5M	12.6M
2022	500.0M	539.0M	454.2M	267.6M
2021	9.0M	10.6M	112.6M	352.4M
2020	4.4M	4.8M	5.2M	5.6M
2019	0	0	0	4.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of iTeos Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 05, 2023	mcgrath yvonne	acquired	-	-	31,000	chief scientific officer
Dec 05, 2023	detheux michel	acquired	-	-	30,000	chief executive officer
Dec 05, 2023	gall matthew	acquired	-	-	41,000	chief financial officer
Dec 05, 2023	call matthew	acquired	-	-	44,000	chief operating officer
Oct 12, 2023	gall matthew	bought	41,850	8.37	5,000	chief financial officer
Aug 23, 2023	boxer capital, llc	sold	-5,692,670	16.2648	-350,000	-
Mar 28, 2023	call matthew	acquired	118,667	2.95	40,226	chief operating officer
Jun 09, 2022	hallal david	sold	-22,846	19.51	-1,171	-
Jun 09, 2022	hallal david	acquired	4,953	4.23	1,171	-
Jun 08, 2022	hallal david	acquired	105,087	3.69454	28,444	-

Which funds bought or sold ITOS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-46.95	-68,389	133,222	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	new	-	1,364	1,364	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	133	237,610	362,210	0.01%
Apr 05, 2024	CWM, LLC	reduced	-32.59	-	1,000	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	new	-	400,989	400,989	-%
Apr 05, 2024	GAMMA Investing LLC	added	11.28	696	2,019	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-97.42	-24,396	646	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-17.8	-3,534,850	16,325,800	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	143	9,580,420	16,251,300	-%

Are Funds Buying or Selling ITOS?

Are funds buying ITOS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ITOS

No. of Funds

Unveiling iTeos Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	ecor1 capital, llc	5.4%	1,944,672	SC 13G
Feb 14, 2024	biotechnology value fund l p	1.9%	671,726	SC 13G/A
Feb 13, 2024	vanguard group inc	4.17%	1,490,942	SC 13G/A
Jan 23, 2024	blackrock inc.	11.9%	4,261,745	SC 13G/A
Jan 09, 2024	millennium management llc	2.7%	967,402	SC 13G/A
Oct 24, 2023	millennium management llc	5.8%	2,090,833	SC 13G
Feb 14, 2023	biotechnology value fund l p	2.7%	975,430	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.11%	1,819,030	SC 13G
Jan 26, 2023	blackrock inc.	12.6%	4,479,421	SC 13G/A

Recent SEC filings of iTeos Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	4	Insider Trading
Mar 07, 2024	3	Insider Trading
Mar 06, 2024	S-8	Employee Benefits Plan
Mar 06, 2024	10-K	Annual Report
Feb 16, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to iTeos Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.9B	6.8B	-1.66%	-28.18%	-8.47	5.83	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-2.46%	-28.84%	-41.72	10.05	76.23%	61.08%
BMRN	16.9B	2.4B	4.57%	-8.46%	100.76	6.98	15.42%	18.43%
INCY	11.7B	3.7B	-10.11%	-29.11%	19.5	3.15	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.75	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-13.81%	-4.67%	-14.08	12.45	440.80%	-27.84%
ARWR	3.0B	240.7M	-20.67%	-25.33%	-10	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.71	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	572.4M	983.7M	-17.39%	-51.52%	-1.05	0.58	-50.36%	17.16%
CRBP	395.6M	881.7K	-0.38%	387.14%	-8.87	466.16	-77.61%	-5.33%
INO	233.7M	4.9M	-10.29%	-2.81%	-1.73	48.02	-54.97%	51.71%
IBIO	6.2M	2.1M	59.81%	33.59%	-0.23	2.14	-13.45%	66.37%

iTeos Therapeutics, Inc. News

Latest updates

iTeos Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-	-	-	-	12,595,000	53,905,000	19,487,000	41,716,000	152,522,000	240,504,000	104,271,000	2,701,000	4,915,000	678,000	2,299,000	1,081,000	1,589,000	1,220,000	851,000	678,000
Operating Expenses	-7.1%	40,208,000	43,280,000	42,621,000	37,525,000	36,522,000	34,692,000	38,381,000	31,711,000	26,983,500	24,863,000	29,339,000	18,689,000	14,941,000	13,525,000	8,531,000	8,243,000	-	7,697,000	5,995,000
S&GA Expenses	-2.1%	12,380,500	12,642,000	13,435,000	11,927,000	11,101,000	10,760,000	11,471,000	10,615,000	9,597,500	8,761,000	15,101,000	7,046,000	5,729,000	4,799,000	2,394,000	2,418,000	-	2,699,000	2,093,000
R&D Expenses	-9.2%	27,827,500	30,638,000	29,186,000	25,598,000	25,421,000	23,932,000	26,910,000	21,096,000	17,386,000	16,102,000	14,238,000	11,643,000	9,212,000	8,726,000	6,137,000	5,825,000	-	4,998,000	3,902,000
EBITDA Margin	-896.9%	-8.59	-0.86	-0.30	0.12	0.56	0.77	0.79	0.78	0.73	0.16	-6.14	-5.12	-6.66	-	-	-	-	-	-
Income Taxes	300.0%	2,362,500	-1,181,000	1,232,000	1,199,000	2,293,000	-2,977,000	2,817,000	49,951,000	39,172,000	2,771,000	-	-	-	-8,000	-50,000	2,000	-	29,000	58,000
Earnings Before Taxes	15.7%	-28,188,000	-33,422,000	-33,068,000	-14,352,000	22,746,000	-1,986,000	8,443,000	119,533,000	224,044,000	72,413,000	-26,459,000	-13,534,000	-14,903,000	-10,688,000	-7,252,000	-	-	-6,892,000	-5,697,000
EBT Margin	-890.9%	-8.66	-0.87	-0.31	0.12	0.56	0.77	0.79	0.78	0.73	0.16	-6.19	-5.17	-6.75	-	-	-	-	-	-
Net Income	5.2%	-30,550,500	-32,241,000	-34,300,000	-15,551,000	20,453,000	991,000	5,626,000	69,582,000	184,872,000	69,642,000	-26,459,000	-13,534,000	-14,904,000	-10,680,000	-7,202,000	-5,247,000	-5,376,000	-6,921,000	-5,755,000
Net Income Margin	-865.6%	-8.94	-0.93	-0.33	0.09	0.36	0.57	0.61	0.60	0.61	0.13	-6.19	-5.16	-6.74	-	-	-	-	-	-
Free Cashflow	56.2%	-15,161,000	-34,641,000	-30,246,000	-26,674,000	-27,290,000	-29,779,000	-30,833,000	-24,229,000	-58,978,000	604,471,000	-18,656,000	-14,878,000	-5,598,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-1.5%	668	678	704	728	755	778	815	850	885	922	319	333	345	351	145	31.00
Current Assets	-11.1%	551	619	615	615	628	769	805	841	875	914	310	325	340	346	140	26.00
Cash Equivalents	23.0%	251	204	216	225	285	752	792	824	849	900	303	322	336	340	137	20.00
Net PPE	41.0%	5.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	1.00	1.00	1.00
Liabilities	16.3%	92.00	79.00	80.00	76.00	92.00	144	177	224	332	550	29.00	20.00	21.00	15.00	12.00	15.00
Current Liabilities	41.8%	40.00	28.00	30.00	26.00	42.00	94.00	125	174	304	542	21.00	12.00	15.00	10.00	8.00	13.00
Shareholder's Equity	-3.9%	575	598	624	652	663	634	637	626	553	372	289	313	323	336	-	-
Retained Earnings	-19.7%	125	155	187	222	237	217	216	210	141	-44.20	-113	-87.43	-73.90	-58.99	-48.31	-35.86
Additional Paid-In Capital	1.6%	464	456	449	442	436	429	424	418	413	407	403	400	396	394	1.00	-
Shares Outstanding	0.1%	36.00	36.00	36.00	36.00	36.00	36.00	36.00	35.00	35.00	35.00	35.00	35.00	35.00	-	-	-
Float	-	-	-	-	-	-	-	-	855	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	59.4%	-13,765	-33,890	-29,546	-26,555	-27,173	-29,696	-30,322	-24,002	-58,816	605,001	-18,255	-14,790	-5,464	-10,231	-10,002	521	-	-	-
Share Based Compensation	1.9%	7,193	7,057	6,964	5,807	5,885	5,723	5,760	4,193	4,041	3,942	3,227	2,584	2,042	1,714	350	186	-	-	-
Cashflow From Investing	171.3%	61,556	22,693	20,103	-31,694	-445,120	-105	-514	-323	-161	-532	-458	-91.00	-134	-105	-101	-37.00	-	-	-
Cashflow From Financing	2970.0%	307	10.00	218	578	1,374	-1.00	278	333	2,356	441	195	667	833	212,873	-1,106	127,739	-	-	-

ITOS Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
License and collaboration revenue	$ 12,595	$ 267,630	$ 344,775
Total revenue	12,595	267,630	344,775
Operating expenses:
Research and development expenses	113,300	97,359	59,369
General and administrative expenses	50,396	43,947	40,505
Total operating expenses	163,696	141,306	99,874
(Loss) income from operations	(151,101)	126,324	244,901
Other income:
Grant income	2,687	2,091	10,181
Research and development tax credits	3,527	1,172	0
Interest income	31,774	11,361	78
Other income, net	4,083	7,788	1,304
(Loss) income before income tax expense	(109,030)	148,736	256,464
Income tax expense	3,612	52,084	41,943
Net (loss) income	(112,642)	96,652	214,521
Net (loss) income attributable to common stockholders	$ (112,642)	$ 96,652	$ 214,521
Basic net (loss) income per common share	$ (3.15)	$ 2.72	$ 6.1
Diluted net (loss) income per common share	$ (3.15)	$ 2.56	$ 5.68
Weighted-average common shares outstanding - basic	35,763,520	35,552,025	35,181,383
Weighted-average common shares outstanding - diluted	35,763,520	37,766,507	37,774,790
Net Income (Loss)	$ (112,642)	$ 96,652	$ 214,521
Foreign currency translation adjustments	(3,631)	(8,478)	(1,635)
Unrealized gain (loss) related to available-for-sale debt securities	35	(148)	0
Comprehensive (loss) income	$ (116,238)	$ 88,026	$ 212,886

ITOS Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 251,177	$ 284,803
Short-term investments (amortized cost of $281,035)	280,739	328,359
Grants receivable	0	1,001
Research and development tax credits receivable	135	0
Refundable income taxes	6,365	1,434
Prepaid expenses and other current assets	12,236	12,701
Total current assets	550,652	628,298
Property and equipment, net	4,696	2,121
Long-term investments (amortized cost of $100,208)	100,539	118,225
Research and development tax credits receivable, net of current portion	4,508	1,128
Restricted cash	274	235
Right of use assets	6,036	4,652
Other assets	883	332
Total assets	667,588	754,991
Current liabilities:
Accounts payable	11,293	7,662
Accrued expenses and other current liabilities	7,058	14,092
Accrued personnel expenses	8,562	5,635
Payable for investments	9,787	0
Deferred income	2,063	1,180
Deferred revenue	0	12,595
Lease liabilities	1,251	836
Total current liabilities	40,014	42,000
Grants repayable	6,609	6,622
Lease liabilities, net of current portion	4,807	3,837
Unrecognized tax benefits	40,930	39,200
Total liabilities	92,360	91,659
Commitments and contingencies (Note 10)
Stockholders’ equity (deficit):
Common stock, $0.001 par value, 150,000,000 shares authorized at December 31, 2023 and 2022, respectively; 35,838,080 and 35,611,219 shares issued and outstanding at December 31, 2023 and 2022, respectively	36	36
Additional paid-in capital	463,799	435,665
Accumulated other comprehensive (loss)	(13,240)	(9,644)
Retained earnings	124,633	237,275
Total stockholders' equity	575,228	663,332
Total liabilities and stockholders' equity	$ 667,588	$ 754,991

About iTeos Therapeutics, Inc.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Michel Detheux Ph.D.
WEBSITE	iteostherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	125

iTeos Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for iTeos Therapeutics, Inc.? What does ITOS stand for in stocks?

ITOS is the stock ticker symbol of iTeos Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iTeos Therapeutics, Inc. (ITOS)?

As of Fri Apr 19 2024, market cap of iTeos Therapeutics, Inc. is 378.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ITOS stock?

You can check ITOS's fair value in chart for subscribers.

What is the fair value of ITOS stock?

You can check ITOS's fair value in chart for subscribers. The fair value of iTeos Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iTeos Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ITOS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iTeos Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ITOS is over valued or under valued. Whether iTeos Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact iTeos Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ITOS.

What is iTeos Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ITOS's PE ratio (Price to Earnings) is -3.36 and Price to Sales (PS) ratio is 30.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ITOS PE ratio will change depending on the future growth rate expectations of investors.